21:11 , Jun 4, 2019 |  BC Extra  |  Financial News

June 4 Financial Quick Takes: Lung Therapeutics' $36M series C; plus Strand, Hansoh, Inhibrx and more

Lung Therapeutics closes $36M series C  Lung Therapeutics Inc. (Austin, Texas) raised $36 million in a series C round led by Bios Partners with participation by undisclosed new and existing investors. Lung has raised $53...
21:52 , May 30, 2019 |  BC Extra  |  Financial News

May 30 Financial Quick Takes: $200M series F for Tempus; plus TFF, Frontage Holdings

Tempus raises $200M for precision medicine platform  Bringing its valuation to $3.1 billion, Tempus Labs Inc. (Chicago, Ill.) raised $200 million in a series F round to expand its precision medicine platform into new therapeutic...
22:05 , May 17, 2019 |  BC Extra  |  Financial News

Actuate gets $21.7M to expand clinical testing of lead candidate

With its $21.7 million series B round, Actuate plans to expand clinical testing of its GSK3B inhibitor into Europe and advance its pediatric neuroblastoma program for the candidate. Kairos Ventures led the round, with participation...
21:10 , Jan 26, 2018 |  BC Week In Review  |  Financial News

Bios provides BIOS Fund II update

Bios Partners (Fort Worth, Texas) said it has raised more than $21.3 million for its proposed BIOS Fund II. Bios told BioCentury that while $50 million is the fund's cap, the final figure is expected...
20:20 , Jun 9, 2017 |  BC Week In Review  |  Financial News

Lung Therapeutics raises $14.3M in series B

On June 6, pulmonary company Lung Therapeutics Inc. (Austin, Texas) raised $14.3 million in a series B round led by Bios Partners. Founding investor UT Horizon Fund also participated. Lung Therapeutics Inc. , Austin, Texas ...
00:07 , Jun 7, 2017 |  BC Extra  |  Company News

Lung Therapeutics raises $14.3M series B round

Lung Therapeutics Inc. (Austin, Texas) raised $14.3 million in a series B round led by Bios Partners. Founding investor UT Horizon Fund also participated. Lung’s lead product LTI-01 , a single-chain urokinase plasminogen activator, is...
16:07 , May 4, 2017 |  BC Week In Review  |  Financial News

Lantern raises $3.7M in series A

On May 2, cancer informatics company Lantern Pharma Inc. (Dallas, Texas) raised $3.7 million in a series A round led by Bios Partners, GPG Ventures and other private investors. Lantern Pharma Inc. , Dallas, Texas ...
04:42 , Apr 7, 2017 |  BC Week In Review  |  Financial News

Azitra completes venture financing

Microbiome play Azitra Inc. (Farmington, Conn.) raised $2.9 million in a series A round led by Bios Partners on April 5. Azitra Inc. , Farmington, Conn. ...
21:33 , Dec 16, 2016 |  BioCentury  |  Emerging Company Profile

Floral delivery

Instability and poor penetration can make topical delivery of proteins and peptides into the skin inefficient and inconsistent. Azitra Inc. is using an engineered human commensal strain of bacteria to consistently deliver therapeutic proteins to...